Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.

[1]  M. Goebeler,et al.  Mepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful? , 2015, Acta dermato-venereologica.

[2]  F. Mastaglia,et al.  Cytokines in immune‐mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications , 2014, Clinical and experimental immunology.

[3]  A. J. da Silva Duarte,et al.  TLR7/TLR8 Activation Restores Defective Cytokine Secretion by Myeloid Dendritic Cells but Not by Plasmacytoid Dendritic Cells in HIV-Infected Pregnant Women and Newborns , 2013, PloS one.

[4]  M. Aringer,et al.  Innate immune processes in lupus erythematosus. , 2013, Clinical immunology.

[5]  L. Criswell,et al.  Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus , 2012, Arthritis Research & Therapy.

[6]  V. Werth,et al.  The interferon‐regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score , 2012, The British journal of dermatology.

[7]  L. León,et al.  Long-term use of antimalarial drugs in rheumatic diseases. , 2012, Clinical and experimental rheumatology.

[8]  J. Reveille,et al.  Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort , 2012, Lupus.

[9]  V. Werth,et al.  Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients , 2012, Arthritis Research & Therapy.

[10]  P. Brown,et al.  Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases , 2012, PloS one.

[11]  V. Werth,et al.  Quality of life in dermatomyositis. , 2011, Journal of the American Academy of Dermatology.

[12]  T. Tenhave,et al.  Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. , 2011, Archives of dermatology.

[13]  M. Chren,et al.  Quality of life in cutaneous lupus erythematosus. , 2011, Journal of the American Academy of Dermatology.

[14]  U. Švajger,et al.  Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines , 2011, The Journal of Immunology.

[15]  C. Coley,et al.  Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument , 2010, The British journal of dermatology.

[16]  P. Calzavara-Pinton,et al.  Treatment of lupus skin involvement with quinacrine and hydroxychloroquine , 2009, Lupus.

[17]  V. Werth,et al.  Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. , 2009, Archives of dermatology.

[18]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[19]  A. Troxel,et al.  The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. , 2008, Archives of dermatology.

[20]  Lars Karlsson,et al.  TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. , 2007, Inflammation & allergy drug targets.

[21]  S. Kalia,et al.  New concepts in antimalarial use and mode of action in dermatology , 2007, Dermatologic therapy.

[22]  S. Gay,et al.  Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling , 2006, Nature Clinical Practice Rheumatology.

[23]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[24]  J. Berlin,et al.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. , 2005, The Journal of investigative dermatology.

[25]  T. Bieber,et al.  Evidence for a role of type I interferons in the pathogenesis of dermatomyositis , 2005, The British journal of dermatology.

[26]  V. Werth,et al.  Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. , 2005, Archives of dermatology.

[27]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  I. Rosner,et al.  The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients , 2000, Lupus.

[29]  M. Kaplan,et al.  Dendritic cells and the immunopathogenesis of systemic lupus erythematosus , 2007, Immunologic research.